Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.67 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.53 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20569350 | 0.87 | SLC6A9 (0.58) | TDP1SLC6A9MAPTHTTALDH1A1 | |
| SCHEMBL2390062 | 0.85 | TDP1 (0.71) | TDP1SLC6A9MAPTNPSR1HTT | |
| SCHEMBL2390327 | 0.83 | ALDH1A1 (0.76) | TDP1SLC6A9MAPTNPSR1HTT | |
| SCHEMBL1844184 | 0.82 | TDP1 (0.71) | TDP1SLC6A9MAPTNPSR1HTT | |
| SCHEMBL1846736 | 0.82 | TDP1 (0.71) | TDP1SLC6A9MAPTNPSR1HTT | |
| SCHEMBL19212191 | 0.81 | SLC6A9 (0.53) | TDP1SLC6A9MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1845390 | 0.81 | LMNA (0.71) | TDP1SLC6A9MAPTNPSR1HTT | |
| SCHEMBL1849301 | 0.81 | TDP1 (1.00) | TDP1SLC6A9MAPTNPSR1HTT | |
| SCHEMBL28239091 | 0.80 | SLC6A9 (0.53) | SLC6A9MAPTALDH1A1SLC6A5SMN1; SMN2 | |
| SCHEMBL30890284 | 0.80 | LMNA (0.65) | SLC6A9MAPTALDH1A1SLC6A5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20190050526-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160283652-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2016-09-29 | — | — | US | disclosed |
| CN-102170882-B | Compositions and methods of treating amyloid disease | TREVENTIS CORP | 2014-04-02 | — | — | CN | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | TDP1 228/4885SLC6A9 4630/4885MAPT 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.